Oscar Health raises outlook on H1 strength, but risk adjustment and membership questions linger

What happened

Oscar Health announced record first-half 2026 profitability and raised its full-year operating outlook, crediting membership growth, disciplined pricing, and lower administrative costs. The upbeat call reinforces the company's operating leverage story, with management citing favorable utilization trends. However, the central risks highlighted in our prior analysis—elevated risk adjustment transfers as a share of premiums, potential membership attrition after enhanced subsidies expired, and the sustainability of Q1's favorable reserve development—remain unaddressed in the headlines. Until Q2's detailed financials confirm whether risk adjustment accrual trended toward the ~20% full-year target and whether net payables stabilized, the raised guidance should be viewed as an early indicator, not a resolution of structural uncertainties. The stock may react positively, but the thesis that reported results can deteriorate on risk adjustment normalization and medical loss ratio reversion still stands without contrary evidence.

Implication

The operating outlook raise suggests that management sees favorable trends continuing, which could push the base case upside if risk adjustment pressures ease. However, the announcement lacks granularity on the risk adjustment payable, MLR drivers, and the impact of expired enhanced subsidies on membership, which were our primary concern. Investors should treat the stock's likely positive reaction with caution and await the 10-Q to assess whether Q1's favorable reserve development reversed or risk adjustment accruals declined. If the Q2 filing confirms that net risk adjustment payable stabilized near $4.0B and accrual ratio fell toward 20%, the bear case probability would shrink, and we might reconsider the rating. Conversely, if the figures show another large build in payables or MLR normalization toward the high end of guidance, the raised outlook would be overshadowed by balance-sheet risk, reinforcing the trimming thesis.

Thesis delta

The raised FY outlook and strong H1 results incrementally reduce the probability of an immediate bear case, but the core risks around risk adjustment and membership attrition remain unresolved. The thesis does not yet shift from POTENTIAL SELL; confirmation requires Q2 regulatory filings showing risk adjustment accrual trending toward management’s ~20% target and a stable net payable.